메뉴 건너뛰기




Volumn 116, Issue 19, 2010, Pages 3735-3742

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: A report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

(19)  Thepot, Sylvain a,b   Itzykson, Raphael a   Seegers, Valerie c   Raffoux, Emmanuel c   Quesnel, Bruno d   Chait, Yasmine e   Sorin, Lucile f   Dreyfus, Francois g   Cluzeau, Thomas h   Delaunay, Jacques i   Sanhes, Laurence j   Eclache, Virginie k   Dartigeas, Caroline l   Turlure, Pascal m   Harel, Stephanie n   Salanoubat, Celia o   Kiladjian, Jean Jacques c   Fenaux, Pierre a,b   Adès, Lionel a,b  


Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARABINOSIDE; AZACITIDINE; HYDROXYUREA; IMATINIB; PIPOBROMAN;

EID: 78149453788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-274811     Document Type: Article
Times cited : (138)

References (35)
  • 1
    • 0019378211 scopus 로고
    • Increased incidence of acute leukemia in polycy-themia vera associated with chlorambucil therapy
    • Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycy-themia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441-447.
    • (1981) N Engl J Med , vol.304 , Issue.8 , pp. 441-447
    • Berk, P.D.1    Goldberg, J.D.2    Silverstein, M.N.3
  • 3
    • 33745714754 scopus 로고    scopus 로고
    • Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia
    • Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4 Pt 2):417-421.
    • (2006) Semin Thromb Hemost , vol.32 , Issue.4 PART 2 , pp. 417-421
    • Kiladjian, J.J.1    Rain, J.D.2    Bernard, J.F.3    Briere, J.4    Chomienne, C.5    Fenaux, P.6
  • 4
    • 72849140307 scopus 로고    scopus 로고
    • Risk stratification for survival and clonal progression in essential thrombocythemia (ET): Result of a prospective study of 108 patients with very long term follow up
    • [abstract]. Abstract 1747
    • Kiladjian J-J, Chevret S, Abgrall J-F, Chait Y, Briere J. Risk stratification for survival and clonal progression in essential thrombocythemia (ET): result of a prospective study of 108 patients with very long term follow up [abstract]. Blood. 2008;112(11):Abstract 1747.
    • (2008) Blood , vol.112 , pp. 11
    • Kiladjian, J.-J.1    Chevret, S.2    Abgrall, J.-F.3    Chait, Y.4    Briere, J.5
  • 6
    • 73949151305 scopus 로고    scopus 로고
    • Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    • Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5587-5593
    • Tam, C.S.1    Kantarjian, H.2    Cortes, J.3
  • 7
    • 60849089645 scopus 로고    scopus 로고
    • Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    • Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
    • (2009) Blood , vol.113 , Issue.6 , pp. 1315-1325
    • Jiang, Y.1    Dunbar, A.2    Gondek, L.P.3
  • 8
    • 0036008494 scopus 로고    scopus 로고
    • INK4ain agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation
    • DOI 10.1046/j.0007-1048.2001.03319.x
    • Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002;116(3):582-586. (Pubitemid 34178657)
    • (2002) British Journal of Haematology , vol.116 , Issue.3 , pp. 582-586
    • Wang, J.C.1    Chen, W.2    Nallusamy, S.3    Chen, C.4    Novetsky, A.D.5
  • 10
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
    • (2009) Lancet Oncol , vol.10 , Issue.3 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 12
    • 58249096418 scopus 로고    scopus 로고
    • 5-Azacitidine has limited therapeutic activity in myelofibrosis
    • Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009;23(1):180-182.
    • (2009) Leukemia , vol.23 , Issue.1 , pp. 180-182
    • Mesa, R.A.1    Verstovsek, S.2    Rivera, C.3
  • 13
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
    • (2009) Blood , vol.114 , Issue.5 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3
  • 14
    • 0019952276 scopus 로고
    • Proposals for the classification of the myelodysplastic syndromes
    • Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
    • (1982) Br J Haematol , vol.51 , Issue.2 , pp. 189-199
    • Bennett, J.M.1    Catovsky, D.2    Daniel, M.T.3
  • 15
    • 0016776911 scopus 로고
    • Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia
    • Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol. 1975;12(4):409-432.
    • (1975) Semin Hematol , vol.12 , Issue.4 , pp. 409-432
    • Laszlo, J.1
  • 16
    • 0016793754 scopus 로고
    • Diagnosis and classification of the polycythemias
    • Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-351.
    • (1975) Semin Hematol , vol.12 , Issue.4 , pp. 339-351
    • Berlin, N.I.1
  • 17
    • 0036786901 scopus 로고    scopus 로고
    • The World Health Organization (WHO) classification of the myeloid neoplasms
    • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
    • (2002) Blood , vol.100 , Issue.7 , pp. 2292-2302
    • Vardiman, J.W.1    Harris, N.L.2    Brunning, R.D.3
  • 18
    • 33745968917 scopus 로고    scopus 로고
    • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
    • (2006) Blood , vol.108 , Issue.2 , pp. 419-425
    • Cheson, B.D.1    Greenberg, P.L.2    Bennett, J.M.3
  • 19
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
    • (2003) J Clin Oncol , vol.21 , Issue.24 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3
  • 20
    • 73949151305 scopus 로고    scopus 로고
    • Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    • Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5587-5593
    • Tam, C.S.1    Kantarjian, H.2    Cortes, J.3
  • 21
    • 33845382806 scopus 로고
    • Non parametric estimation from incomplete observation
    • Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assos. 1958;53:457.
    • (1958) J Am Stat Assos , vol.53 , pp. 457
    • Kaplan, E.1    Meier, P.2
  • 22
    • 0000336139 scopus 로고
    • Regression models and life-tables (with discussion)
    • Cox D. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:487.
    • (1972) J R Stat Soc B , vol.34 , pp. 487
    • Cox, D.1
  • 23
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
    • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
    • (2006) Cancer , vol.106 , Issue.8 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 24
    • 0025778623 scopus 로고
    • Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients
    • Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85(3):124-127.
    • (1991) Acta Haematol , vol.85 , Issue.3 , pp. 124-127
    • Cervantes, F.1    Tassies, D.2    Salgado, C.3    Rovira, M.4    Pereira, A.5    Rozman, C.6
  • 25
    • 12844284481 scopus 로고    scopus 로고
    • Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases
    • DOI 10.1182/blood-2004-07-2864
    • Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977. (Pubitemid 40170863)
    • (2005) Blood , vol.105 , Issue.3 , pp. 973-977
    • Mesa, R.A.1    Li, C.-Y.2    Ketterling, R.P.3    Schroeder, G.S.4    Knudson, R.A.5    Tefferi, A.6
  • 26
    • 52649131772 scopus 로고    scopus 로고
    • The natural history and treatment outcome of blast phase BCR-ABL- Myeloproliferative neoplasms
    • Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112(5):1628-1637.
    • (2008) Blood , vol.112 , Issue.5 , pp. 1628-1637
    • Tam, C.S.1    Nussenzveig, R.M.2    Popat, U.3
  • 28
    • 0033572876 scopus 로고    scopus 로고
    • Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
    • DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0. CO;2-A
    • Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86(12):2632-2641. (Pubitemid 30004667)
    • (1999) Cancer , vol.86 , Issue.12 , pp. 2632-2641
    • Sacchi, S.1    Kantarjian, H.M.2    O'Brien, S.3    Cortes, J.4    Rios, M.B.5    Giles, F.J.6    Beran, M.7    Koller, C.A.8    Keating, M.J.9    Talpaz, M.10
  • 29
    • 33644846509 scopus 로고    scopus 로고
    • Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction?
    • Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107-116.
    • (2006) Nat Rev Cancer , vol.6 , Issue.2 , pp. 107-116
    • Baylin, S.B.1    Ohm, J.E.2
  • 32
    • 33847223121 scopus 로고    scopus 로고
    • Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
    • DOI 10.1038/sj.leu.2404513, PII 2404513
    • Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21(3):505-510. (Pubitemid 46306562)
    • (2007) Leukemia , vol.21 , Issue.3 , pp. 505-510
    • Jost, E.1    Do O, N.2    Dahl, E.3    Maintz, C.E.4    Jousten, P.5    Habets, L.6    Wilop, S.7    Herman, J.G.8    Osieka, R.9    Galm, O.10
  • 33
    • 55549126446 scopus 로고    scopus 로고
    • Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
    • Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008;93(11):1635-1644.
    • (2008) Haematologica , vol.93 , Issue.11 , pp. 1635-1644
    • Fourouclas, N.1    Li, J.2    Gilby, D.C.3
  • 34
    • 55049114480 scopus 로고    scopus 로고
    • Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis
    • Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008;26(8):1920-1930.
    • (2008) Stem Cells , vol.26 , Issue.8 , pp. 1920-1930
    • Bogani, C.1    Ponziani, V.2    Guglielmelli, P.3
  • 35
    • 70349975711 scopus 로고    scopus 로고
    • JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin
    • Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819-822.
    • (2009) Nature , vol.461 , Issue.7265 , pp. 819-822
    • Dawson, M.A.1    Bannister, A.J.2    Gottgens, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.